• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Pulmonology

Dexamethasone treatment for the acute respiratory distress syndrome

byAlex ChanandRavi Shah, MD MBA
February 24, 2020
in Pulmonology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

RELATED REPORTS

The RECOVERY trial: Dexamethasone decreased mortality in hospitalized COVID-19 patients [Classics Series]

COVID-19 pneumonia patients in Wuhan, China [Classics Series]

High dose dexamethasone does not improve survival in patients with hypoxemic respiratory failure due to COVID-19

1. Study findings suggest that early administration of intravenous dexamethasone during acute respiratory distress syndrome may decrease duration of mechanical ventilation and mortality rates.

Evidence Level: 1 (Excellent)

Acute respiratory distress syndrome (ARDS), characterized by acute hypoxemic respiratory failure and bilateral pulmonary infiltrates, is associated with significant mortality rates and currently have no proven pharmacological therapies. Although a previous meta-analysis provided evidence for the potential application of corticosteroids as a treatment option, there has been insufficient evidence to suggest a mortality benefit. In this multicenter, randomized controlled trial, 277 patients with established moderate-to-severe ARDS in a network of 17 intensive care units (ICUs) in Spain were enrolled and assigned to either serve as controls or receive intravenous (IV) dexamethasone during their hospital stay. The primary outcome measure was the number of ventilator-free days at 28 days (defined as days alive and free from mechanical ventilation from day of randomization to day 28), and the secondary outcome measure was all-cause mortality 60 days after randomization. The treatment group, which received 20mg of IV dexamethasone once daily from day 1 to day 5 and 10mg IV dexamethasone once daily day 6 to day 10, was observed to have significantly greater ventilator-free days versus controls (between-group difference 4.8 days [95% CI 2.57 to 7.03]; p<0.0001). All-cause mortality at 60 days was also significantly lower in the treatment group compared to control, with 21% in the former and 36% in the latter (between group difference -15.3% [95% CI -25.9 to -4.9]; p<0.005). This is the first randomized trial testing the efficacy of dexamethasone in patients with ARDS, and suggests that early therapy with dexamethasone could potentially modify the host immune response leading to greater ventilator free days and pose a mortality benefit. With further investigation, dexamethasone may present itself as one of the first pharmacologic therapies for the treatment of ARDS.

Click to read the study in Lancet Respiratory Medicine

Image: PD

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: acute respiratory distress syndrome (ARDS)dexamethasonerespiratory failuresteroids
Previous Post

Associations of Processed Meat, Unprocessed Red Meat, Poultry, or Fish Intake With Incident Cardiovascular Disease and All-Cause Mortality

Next Post

Long-Term Outcomes Associated With Total Arterial Revascularization vs Non-Total Arterial Revascularization

RelatedReports

The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
COVID-19 Classics

The RECOVERY trial: Dexamethasone decreased mortality in hospitalized COVID-19 patients [Classics Series]

July 16, 2022
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
COVID-19 Classics

COVID-19 pneumonia patients in Wuhan, China [Classics Series]

July 8, 2022
Novel coronavirus identified from patients with pneumonia in Wuhan, China
Chronic Disease

High dose dexamethasone does not improve survival in patients with hypoxemic respiratory failure due to COVID-19

July 7, 2022
#VisualAbstract: Oral methylprednisolone may reduce risk of progressive renal failure in patients with IgA nephropathy: TESTING Trial
StudyGraphics

#VisualAbstract: Oral methylprednisolone may reduce risk of progressive renal failure in patients with IgA nephropathy: TESTING Trial

June 2, 2022
Next Post
Cognitive outcomes in older adults undergoing cardiovascular procedures unclear

Long-Term Outcomes Associated With Total Arterial Revascularization vs Non-Total Arterial Revascularization

#VisualAbstract: Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo

#VisualAbstract: Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo

Concussion or mild traumatic brain injury linked with increased risk of suicide

Predicting Death By Suicide Following An Emergency Department Visit For Parasuicide With Administrative Health Care System Data and Machine Learning

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Provision of 1-year mortality data for patients hospitalized with heart failure does not influence clinical decision-making – The REVEAL-HF trial
  • Genetic risk for hemochromatosis associated with abnormal iron deposition localized to motor circuits of the brain
  • Graded sensorimotor retraining may improve chronic lower back pain compared to sham procedure: The RESOLVE randomized clinical trial
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.